These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 17673491)

  • 1. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis.
    Miceli-Richard C; Comets E; Verstuyft C; Tamouza R; Loiseau P; Ravaud P; Kupper H; Becquemont L; Charron D; Mariette X
    Ann Rheum Dis; 2008 Apr; 67(4):478-84. PubMed ID: 17673491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.
    Criswell LA; Lum RF; Turner KN; Woehl B; Zhu Y; Wang J; Tiwari HK; Edberg JC; Kimberly RP; Moreland LW; Seldin MF; Bridges SL
    Arthritis Rheum; 2004 Sep; 50(9):2750-6. PubMed ID: 15457442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential gene expression profiles may differentiate responder and nonresponder patients with rheumatoid arthritis for methotrexate (MTX) monotherapy and MTX plus tumor necrosis factor inhibitor combined therapy.
    Oliveira RD; Fontana V; Junta CM; Marques MM; Macedo C; Rassi DM; Passos GA; Donadi EA; Louzada-Junior P
    J Rheumatol; 2012 Aug; 39(8):1524-32. PubMed ID: 22753658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
    Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
    Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients chosen for treatment with cyclosporine because of severe rheumatoid arthritis are more likely to carry HLA-DRB1 shared epitope alleles, and have earlier disease onset.
    González-Gay MA; Hajeer AH; García-Porrúa C; Dababneh A; Thomson W; Ollier WE; Mattey DL
    J Rheumatol; 2002 Feb; 29(2):271-5. PubMed ID: 11842822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA.
    Kimel M; Cifaldi M; Chen N; Revicki D
    J Rheumatol; 2008 Feb; 35(2):206-15. PubMed ID: 18085743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of HLA-DR on susceptibility to rheumatoid arthritis is influenced by the associated lymphotoxin alpha-tumor necrosis factor haplotype.
    Newton J; Brown MA; Milicic A; Ackerman H; Darke C; Wilson JN; Wordsworth BP; Kwiatkowski D
    Arthritis Rheum; 2003 Jan; 48(1):90-6. PubMed ID: 12528108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissection of class III major histocompatibility complex haplotypes associated with rheumatoid arthritis.
    Newton JL; Harney SM; Timms AE; Sims AM; Rockett K; Darke C; Wordsworth BP; Kwiatkowski D; Brown MA
    Arthritis Rheum; 2004 Jul; 50(7):2122-9. PubMed ID: 15248209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-DRB1 genotype influences risk for and severity of rheumatoid arthritis.
    Meyer JM; Evans TI; Small RE; Redford TW; Han J; Singh R; Moxley G
    J Rheumatol; 1999 May; 26(5):1024-34. PubMed ID: 10332964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour necrosis factor 5' promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families.
    Waldron-Lynch F; Adams C; Amos C; Zhu DK; McDermott MF; Shanahan F; Molloy MG; O'Gara F
    Genes Immun; 2001 Apr; 2(2):82-7. PubMed ID: 11393661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
    Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
    Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
    Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
    Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
    Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE; Kapetanovic MC; Gülfe A; Söderlin M; Saxne T; Geborek P
    Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
    Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
    Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients.
    Martinez A; Salido M; Bonilla G; Pascual-Salcedo D; Fernandez-Arquero M; de Miguel S; Balsa A; de la Concha EG; Fernandez-Gutierrez B
    Arthritis Rheum; 2004 Apr; 50(4):1077-82. PubMed ID: 15077289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
    Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
    Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between tumor necrosis factor-alpha (TNF-alpha) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update.
    Lee YH; Ji JD; Bae SC; Song GG
    J Rheumatol; 2010 Apr; 37(4):740-6. PubMed ID: 20194454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.